抓表面现象：NECTIN-4 可作为恩福妥滨单抗耐药的替代标志物。
Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
机构信息
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
出版信息
Clin Cancer Res. 2023 Apr 14;29(8):1377-1380. doi: 10.1158/1078-0432.CCR-22-3882.
Abstract
Clinical data with enfortumab vedotin (EV) suggest that most bladder cancers overexpress NECTIN-4. A recent article shows that NECTIN-4 membranous expression changes with progression to metastatic disease and that low NECTIN-4 expression in metastatic biopsies is potentially associated with EV resistance. These data argue for incorporation of NECTIN-4 expression into future biomarker strategies. See related article by Klümper et al., p. 1496.
摘要
临床数据显示，大多数膀胱癌过度表达NECTIN-4，而依维莫司（EV）对此有效。最近的一篇文章表明，NECTIN-4 的膜表达随着转移性疾病的进展而变化，转移性活检中低 NECTIN-4 表达可能与 EV 耐药有关。这些数据表明需要将 NECTIN-4 表达纳入未来的生物标志物策略中。Klümper 等人的相关文章见第 1496 页。
相似文献
1
Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.抓表面现象：NECTIN-4 可作为恩福妥滨单抗耐药的替代标志物。
Clin Cancer Res. 2023 Apr 14;29(8):1377-1380. doi: 10.1158/1078-0432.CCR-22-3882.
2
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.膜层粘连蛋白 4 的表达在尿路上皮癌转移过程中经常下降，并与恩福妥单抗 vedotin 的耐药性相关。
Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764.
3
Exploring membranous NECTIN-4 expression patterns and enfortumab vedotin response in prostate cancer.探索前列腺癌中膜型 NECTIN-4 的表达模式和 enfortumab vedotin 的反应。
J Cell Mol Med. 2024 Jul;28(14):e18572. doi: 10.1111/jcmm.18572.
4
Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.与恩福妥滨单抗相关的皮肤毒性的临床和直接免疫荧光特征。
Br J Dermatol. 2022 Jul;187(1):126-127. doi: 10.1111/bjd.21022. Epub 2022 Apr 19.
5
Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.尿路上皮癌中抗NECTIN4抗体药物偶联物恩诺单抗反应的生物标志物
Eur Urol Focus. 2024 Mar;10(2):224-226. doi: 10.1016/j.euf.2024.04.001. Epub 2024 Apr 16.
6
[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].[抗NECTIN-4抗体药物偶联物作为转移性尿路上皮癌患者的一种新治疗选择]
Urologie. 2023 Nov;62(11):1193-1199. doi: 10.1007/s00120-023-02175-5. Epub 2023 Sep 1.
7
The biology and rationale of targeting nectin-4 in urothelial carcinoma.靶向尿路上皮癌中 nectin-4 的生物学和原理。
Nat Rev Urol. 2021 Feb;18(2):93-103. doi: 10.1038/s41585-020-00394-5. Epub 2020 Nov 25.
8
Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.抗体药物偶联物靶向 nectin-4 治疗尿路上皮癌。
Expert Opin Biol Ther. 2021 Jul;21(7):863-873. doi: 10.1080/14712598.2021.1929168. Epub 2021 May 24.
9
Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.恩扎妥昔单抗（一种靶向Nectin-4的抗体药物偶联物）相关的擦烂性红斑在一例转移性尿路上皮癌患者中的病例报告：分子靶向性皮疹的免疫组织化学证据
J Dermatol. 2022 Dec;49(12):e453-e454. doi: 10.1111/1346-8138.16567. Epub 2022 Sep 2.
10
Enfortumab vedotin in the treatment of urothelial cancers and beyond.安维汀（Enfortumab vedotin）在尿路上皮癌及其他癌症治疗中的应用
Future Oncol. 2022 Sep;18(27):3067-3084. doi: 10.2217/fon-2022-0328. Epub 2022 Aug 25.
引用本文的文献
1
Emerging evidence of targeting non-oncogenic drivers for gastric cancer: Claudin18.2 and beyond.针对胃癌非致癌驱动因子的新证据：Claudin18.2及其他。
Ther Adv Med Oncol. 2025 Jun 16;17:17588359251344804. doi: 10.1177/17588359251344804. eCollection 2025.
2
Targeting the tumour cell surface in advanced prostate cancer.靶向晚期前列腺癌的肿瘤细胞表面
Nat Rev Urol. 2025 Apr 1. doi: 10.1038/s41585-025-01014-w.
3
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer.恩杂鲁胺与帕博利珠单抗联合治疗局部晚期或转移性尿路上皮癌成功开发的机制性见解。
Cancers (Basel). 2024 Sep 4;16(17):3071. doi: 10.3390/cancers16173071.
4
Therapeutic prospects of nectin-4 in cancer: applications and value.Nectin-4在癌症治疗中的前景：应用与价值
Front Oncol. 2024 Mar 28;14:1354543. doi: 10.3389/fonc.2024.1354543. eCollection 2024.
5
Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?重新审视转移性尿路上皮癌的治疗：顺铂和铂类不适用标准现状如何？
Biomedicines. 2024 Feb 26;12(3):519. doi: 10.3390/biomedicines12030519.
6
Durable Response After Combination Therapy With Enfortumab Vedotin and Radiotherapy in Metastatic Urothelial Carcinoma: A Report of Two Cases.恩杂鲁胺与放疗联合治疗转移性尿路上皮癌后的持久反应：两例报告
Cureus. 2023 Dec 4;15(12):e49936. doi: 10.7759/cureus.49936. eCollection 2023 Dec.
7
Precision Medicine to Treat Urothelial Carcinoma-The Way Forward.精准医学治疗尿路上皮癌——前进之路
Cancers (Basel). 2023 Jun 1;15(11):3024. doi: 10.3390/cancers15113024.
本文引用的文献
1
Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.基因组异质性是膀胱癌精准肿瘤学的障碍。
Cell Rep. 2022 Dec 20;41(12):111859. doi: 10.1016/j.celrep.2022.111859.
2
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.膜层粘连蛋白 4 的表达在尿路上皮癌转移过程中经常下降，并与恩福妥单抗 vedotin 的耐药性相关。
Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764.
3
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.恩福妥单抗维地昔妥单抗联合帕博利珠单抗治疗既往未治疗的晚期尿路上皮癌。
J Clin Oncol. 2023 Jan 1;41(1):22-31. doi: 10.1200/JCO.22.01643. Epub 2022 Aug 30.
4
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate.克服抗连接蛋白 4 抗体药物偶联物的耐药性。
Mol Cancer Ther. 2022 Jul 5;21(7):1227-1235. doi: 10.1158/1535-7163.MCT-22-0013.
5
Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer.三阴性乳腺癌中 sacituzumab govitecan 获得性临床耐药的多克隆发生与抗原和有效载荷靶点的平行基因组改变有关。
Cancer Discov. 2021 Oct;11(10):2436-2445. doi: 10.1158/2159-8290.CD-21-0702. Epub 2021 Aug 17.
6
New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?新主题：依维莫司与替西罗莫司在肾细胞癌中的疗效比较：我们目前了解多少？
Urol Oncol. 2021 Oct;39(10):619-622. doi: 10.1016/j.urolonc.2021.05.013. Epub 2021 Jun 18.
7
Heterogeneity in Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.尿路上皮癌分子亚型间表达的异质性介导了对恩福妥单抗的敏感性。
Clin Cancer Res. 2021 Sep 15;27(18):5123-5130. doi: 10.1158/1078-0432.CCR-20-4175. Epub 2021 Jun 9.
8
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.在铂类不耐受的晚期尿路上皮癌患者中，在使用PD-1或PD-L1抑制剂后使用恩杂鲁胺（EV‑201）：一项多中心、单臂、2期试验。
Lancet Oncol. 2021 Jun;22(6):872-882. doi: 10.1016/S1470-2045(21)00094-2. Epub 2021 May 12.
9
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.EV-101：一项在包括转移性尿路上皮癌在内的 nectin-4 阳性实体瘤患者中单用恩妥昔单抗 Vedotin 的 I 期研究。
J Clin Oncol. 2020 Apr 1;38(10):1041-1049. doi: 10.1200/JCO.19.02044. Epub 2020 Feb 7.
10
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.肿瘤突变负荷可预测多种癌症类型免疫治疗后的生存情况。
Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.
Zotero 插件